niacinamide has been researched along with Cancer of Stomach in 27 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this phase I study was to evaluate the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with S-1 plus CDDP." | 2.79 | A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. ( Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014) |
| "NNMT was highly expressed in gastric cancer tissues and was negatively correlated with the prognosis of patients with gastric cancer." | 1.62 | [Expression of nicotinamide-N-methyltransferase in gastric cancer and its biological and clinicopathological significance]. ( Liang, W; Sun, F; Wen, Z; Zhang, Q; Zhong, Y, 2021) |
| " Herein, we report a lipid-coated nanodiamond (ND) system loading water-insoluble sorafenib (SND) to improve the bioavailability and efficacy on suppression of cancer metastasis." | 1.40 | The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. ( Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J, 2014) |
| "Treatment of sorafenib significantly decreased phosphorylation activation of ERK protein in a dose-dependent manner." | 1.40 | Sorafenib regulating ERK signals pathway in gastric cancer cell. ( En, LM; Hao, L; Ju, H; Juan, LW; Kai, HY, 2014) |
| "They effectively inhibited gastric cancer cell proliferation and induced G0/G1 phase arrest." | 1.40 | The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. ( Chen, S; Lin, H; Tao, C, 2014) |
| "Sorafenib treatment also caused up-regulation of p-c-Raf Ser338 and p-extracellular signal-regulated kinase (ERK) Thr202/Tyr204 in gastric cancer xenografts." | 1.35 | AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. ( Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S, 2009) |
| "Lastly, the first effective medical treatment of hepatocellular carcinoma has been presented." | 1.35 | [News in digestive oncology]. ( Di Fiore, F; Michel, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, DH | 1 |
| Lee, S | 1 |
| Kang, HG | 1 |
| Park, HW | 1 |
| Lee, HW | 1 |
| Kim, D | 1 |
| Yoem, DH | 1 |
| Ahn, JH | 1 |
| Ha, E | 1 |
| You, WK | 1 |
| Lee, SH | 1 |
| Kim, SJ | 1 |
| Chun, KH | 1 |
| Wen, Z | 1 |
| Liang, W | 1 |
| Zhong, Y | 1 |
| Sun, F | 1 |
| Zhang, Q | 1 |
| Li, T | 1 |
| Zhang, Y | 1 |
| Meng, YP | 1 |
| Bo, LS | 1 |
| Ke, WB | 1 |
| Choi, KM | 1 |
| Cho, E | 1 |
| Kim, E | 1 |
| Shin, JH | 1 |
| Kang, M | 1 |
| Kim, B | 1 |
| Han, EH | 1 |
| Chung, YH | 1 |
| Kim, JY | 1 |
| Yamada, Y | 1 |
| Kiyota, N | 1 |
| Fuse, N | 1 |
| Kato, K | 1 |
| Minami, H | 1 |
| Hashizume, K | 1 |
| Kuroki, Y | 1 |
| Ito, Y | 1 |
| Ohtsu, A | 1 |
| Awazu, Y | 1 |
| Nakamura, K | 1 |
| Mizutani, A | 1 |
| Kakoi, Y | 1 |
| Iwata, H | 1 |
| Yamasaki, S | 1 |
| Miyamoto, N | 1 |
| Imamura, S | 1 |
| Miki, H | 1 |
| Hori, A | 1 |
| Martin-Richard, M | 1 |
| Gallego, R | 1 |
| Pericay, C | 1 |
| Garcia Foncillas, J | 1 |
| Queralt, B | 1 |
| Casado, E | 1 |
| Barriuso, J | 1 |
| Iranzo, V | 1 |
| Juez, I | 1 |
| Visa, L | 1 |
| Saigi, E | 1 |
| Barnadas, A | 1 |
| Garcia-Albeniz, X | 1 |
| Maurel, J | 1 |
| Zhang, Z | 1 |
| Niu, B | 1 |
| Chen, J | 1 |
| He, X | 1 |
| Bao, X | 1 |
| Zhu, J | 1 |
| Yu, H | 1 |
| Li, Y | 1 |
| Juan, LW | 1 |
| En, LM | 1 |
| Hao, L | 1 |
| Kai, HY | 1 |
| Ju, H | 1 |
| Tao, C | 1 |
| Lin, H | 1 |
| Chen, S | 1 |
| Huang, YS | 1 |
| Xue, Z | 1 |
| Zhang, H | 1 |
| Janjigian, YY | 1 |
| Vakiani, E | 1 |
| Ku, GY | 1 |
| Herrera, JM | 1 |
| Tang, LH | 2 |
| Bouvier, N | 1 |
| Viale, A | 1 |
| Socci, ND | 1 |
| Capanu, M | 1 |
| Berger, M | 1 |
| Ilson, DH | 1 |
| Yang, YC | 1 |
| Cai, J | 1 |
| Yin, J | 1 |
| Zhang, J | 1 |
| Wang, KL | 1 |
| Zhang, ZT | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Ni, Y | 1 |
| Yao, Z | 1 |
| Ye, L | 1 |
| Tian, J | 1 |
| Komuro, A | 1 |
| Yashiro, M | 1 |
| Iwata, C | 1 |
| Morishita, Y | 1 |
| Johansson, E | 1 |
| Matsumoto, Y | 1 |
| Watanabe, A | 1 |
| Aburatani, H | 1 |
| Miyoshi, H | 1 |
| Kiyono, K | 1 |
| Shirai, YT | 1 |
| Suzuki, HI | 1 |
| Hirakawa, K | 1 |
| Kano, MR | 1 |
| Miyazono, K | 1 |
| Yang, S | 1 |
| Ngo, VC | 1 |
| Lew, GB | 1 |
| Chong, LW | 1 |
| Lee, SS | 1 |
| Ong, WJ | 1 |
| Lam, WL | 1 |
| Thng, CH | 1 |
| Koong, HN | 1 |
| Ong, HS | 1 |
| Chung, A | 1 |
| Chow, P | 1 |
| Lee, J | 1 |
| Soo, KC | 1 |
| Huynh, H | 1 |
| Tesei, A | 1 |
| Leonetti, C | 1 |
| Zupi, G | 1 |
| Scarsella, M | 1 |
| Brigliadori, G | 1 |
| Ulivi, P | 1 |
| Fabbri, F | 1 |
| Arienti, C | 1 |
| Amadori, D | 1 |
| Passardi, A | 1 |
| Silvestrini, R | 1 |
| Zoli, W | 1 |
| Boonstra, JJ | 1 |
| van Marion, R | 1 |
| Beer, DG | 1 |
| Lin, L | 1 |
| Chaves, P | 1 |
| Ribeiro, C | 1 |
| Pereira, AD | 1 |
| Roque, L | 1 |
| Darnton, SJ | 1 |
| Altorki, NK | 1 |
| Schrump, DS | 1 |
| Klimstra, DS | 1 |
| Eshleman, JR | 1 |
| Alvarez, H | 1 |
| Shimada, Y | 1 |
| van Dekken, H | 1 |
| Tilanus, HW | 1 |
| Dinjens, WN | 1 |
| Sun, W | 1 |
| Powell, M | 1 |
| O'Dwyer, PJ | 1 |
| Catalano, P | 1 |
| Ansari, RH | 1 |
| Benson, AB | 1 |
| Kim, C | 1 |
| Lee, JL | 1 |
| Choi, YH | 1 |
| Kang, BW | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Kang, YK | 1 |
| Jagannathan, JP | 1 |
| Ramaiya, NH | 1 |
| Shinagare, AB | 1 |
| Hornick, JL | 1 |
| George, S | 1 |
| KALASHNIKOV, AP | 1 |
| Hampton, T | 1 |
| Michel, P | 1 |
| Di Fiore, F | 1 |
| Nagaishi, A | 1 |
| Tanabe, H | 1 |
| Ueno, M | 1 |
| Matsui, M | 2 |
| Bremener, SM | 1 |
| Virin, IIa | 1 |
| Zubkova, EI | 1 |
| Rogova, KP | 1 |
| Lorenz, W | 1 |
| Halbach, S | 1 |
| Gerant, M | 1 |
| Werle, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer[NCT00917462] | Phase 2 | 35 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT00253370] | Phase 2 | 44 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie[NCT01503372] | Phase 2 | 75 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00917462)
Timeframe: every week while on study
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib | 35 |
(NCT00917462)
Timeframe: anytime prior to enrollment or during protocol therapy
| Intervention | % of tumors with high pERK expression (Number) |
|---|---|
| Sorafenib | 65 |
Overall survival was defined as the time from registration to death from any cause. (NCT00253370)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; then every 6 months if patient is 2-3 years from study entry.
| Intervention | Months (Median) |
|---|---|
| BAY 43-9006, Docetaxel, Cisplatin | 13.6 |
"Progression-free survival was defined as the shorter of:~The time from registration to progression. or~The time from registration to death without documentation of progression given that the death occurs within 4 months of the last disease assessment without progression (or registration, whichever is more recent).~Therefore, cases not meeting either of the criteria for a PFS event are censored at the date of last disease assessment without progression (or registration, whichever is more recent).~Progression is defined as at least 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing non-target lesions." (NCT00253370)
Timeframe: Assessed every 6 weeks until disease progression or up to 3 years
| Intervention | Months (Median) |
|---|---|
| BAY 43-9006, Docetaxel, Cisplatin | 5.8 |
Response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= >=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Objective response = CR + PR. (NCT00253370)
Timeframe: Assessed every 6 weeks until disease progression or up to 3 years
| Intervention | Proportion of patients (Number) |
|---|---|
| BAY 43-9006, Docetaxel, Cisplatin | 0.409 |
5 trials available for niacinamide and Cancer of Stomach
| Article | Year |
|---|---|
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; F | 2014 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2013 |
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm | 2015 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisp | 2010 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisp | 2010 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisp | 2010 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisp | 2010 |
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cispla | 2012 |
22 other studies available for niacinamide and Cancer of Stomach
| Article | Year |
|---|---|
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Calcium-Binding Proteins; Cel | 2020 |
[Expression of nicotinamide-N-methyltransferase in gastric cancer and its biological and clinicopathological significance].
Topics: Cell Proliferation; Humans; Niacinamide; Nicotinamide N-Methyltransferase; Prognosis; Stomach Neopla | 2021 |
miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; | 2017 |
Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Topics: Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Imidazoles; Mitogen-Activated Prote | 2018 |
A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gene Expr | 2013 |
The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Humans | 2014 |
Sorafenib regulating ERK signals pathway in gastric cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expressi | 2014 |
The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; G1 Phase Cell Cyc | 2014 |
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2015 |
Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; Heparin; Humans; Mi | 2016 |
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cel | 2016 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Prolife | 2009 |
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models | 2009 |
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesu | 2011 |
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, | 2010 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neo | 2012 |
[THE LEVEL OF NICOTINIC ACID DERIVATIVES AND THEIR EXCRETION IN PATIENTS WITH GASTRIC AND PULMONARY CANCER].
Topics: Humans; Lung Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Stomach Neoplasms | 1964 |
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2007 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Comb | 2008 |
[Case of non-alcoholic pellagra following gastrectomy].
Topics: Aged; Gastrectomy; Humans; Infusions, Intravenous; Male; Niacinamide; Pellagra; Stomach Neoplasms; T | 2008 |
[On the metabolism of vitamins B6, B12, C, PP and panthothenic acid in stomach cancer patients].
Topics: Adult; Female; Humans; Male; Middle Aged; Niacinamide; Pantothenic Acid; Pyridoxine; Stomach Neoplas | 1965 |
Specific histidine decarboxylases in the gastric mucosa of man and other mammals. Determination, location and properties.
Topics: Adenocarcinoma; Animals; Benzene; Carboxy-Lyases; Cats; Cattle; Chlorpromazine; Chromatography, Gel; | 1969 |